For example, the profile of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in the Oncolines® cancer cell line panel shows similarity with that of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (5). This evidence concerns the gene BTK and cancer.